In this work, we first developed a bispecific Tandem CAR, cloning an anti-CD146 scFv together with an anti-CD33 scFv, to address the hypothesis of targeting both AML blasts and MSCs within the BM niche. This evidence concerns the gene MCAM and acute myeloid leukemia.